September 2, 2023 – ENHERTU® Granted Two Breakthrough Therapy Designations In U.S. For Patients Across Multiple HER2 Expressing Cancers

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, and for the treatment of…

Read More

July 3, 2023 – High prevalence of vitamin B-12 deficiency before and early after gastrectomy in patients with gastric cancer

Gastrectomy causes vitamin B-12 deficiency since vitamin B-12 requires gastric acid and intrinsic factor for its absorption. Vitamin B-12 deficiency is considered to develop years after gastrectomy because of large hepatic storage. However, most gastric cancer develops after long-standing atrophic gastritis with vitamin B-12 malabsorption. We have investigated vita-min B-12 status in 22 patients before…

Read More

May 24, 2023 – Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies

CLAUDIN-18 Splice Variant 2 (claudin-18.2; CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.1 Multiple clinical trials of CLDN18.2-targeted therapies, including…

Read More